Evidence map›Paper›PMID 34499199›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Blockade of TGF-βR improves the efficacy of doxorubicin by modulating the tumor cell motility and affecting the immune cells in a melanoma model.

Alireza Mardomi, Marzieh Ghollasi, Mohsen Korani, Mahsa Panahi, Mohammad Parsa-Kondelaji, Mehdi Sabzichi, Ali Salimi

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Alireza MardomiKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Marzieh GhollasiDepartment of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
Mohsen KoraniChemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mahsa PanahiKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad Parsa-KondelajiDepartment of Hematology and Blood Bank, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mehdi SabzichiStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali SalimiNanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. salimiali@bmsu.ac.ir.
Baqiyatallah University of Medical Sciences · IRTabriz University of Medical Sciences · IRKharazmi University · IRMashhad University of Medical Sciences · IR

Funding

Mazandaran University of Medical Sciences MAZUMS.SRC.16/97
6 · The paper itself

Abstract

TGF-β contributes to drug resistance and the invasiveness of tumor cells and weakens the anti-tumor immune responses. The present study aimed at examining the efficacy of the combination of SB431542, as a specific inhibitor of TGF-βR, and doxorubicin in controlling the melanoma tumor in mice. The impact of the combination of the doxorubicin and SB431542 on the cell growth, apoptosis, migration, and invasiveness of B16-F10 cells was examined. Besides, the B16-F10 tumor was induced in C57BL/6 mice, and the effects of the mentioned treatment on the tumor volume, survival, and the exhaustion state of T cells were evaluated. Although the combination of doxorubicin and SB431542 did not exhibit synergism in the inhibition of cell growth and apoptosis induction, it efficiently prohibited the migration and the epithelial to mesenchymal transition of B16-F10 cells, and the combination of doxorubicin and SB431542 caused an increase in mRNA levels of E-cadherin and, on the other hand, led to a decline in the expression of Vimentin. Tumor volume and the survival of tumor-bearing mice were efficiently controlled by the combination therapy. This treatment also eventuated in a decrease in the percentage of PD-L1

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBenzamidesCadherinsCell MovementDioxolesDoxorubicinEpithelial-Mesenchymal TransitionFemaleMelanoma, ExperimentalMiceMice, Inbred C57BLNeoplasm InvasivenessRAW 264.7 CellsReceptors, Transforming Growth Factor beta4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideBenzamidesCadherinsCdh1 protein, mouseDioxolesDoxorubicinReceptors, Transforming Growth Factor betaVimentinVim protein, mouseDoxorubicinEMTMacrophage polarizationSB431542TGF-β

Identifiers

PMID34499199
OpenAlexW3197156510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.